Baidu
map

JAMA:心梗后患者ICD置入率和死亡风险

2015-07-08 小田 译 医学论坛网

置入心脏复律除颤器(ICD)不被推荐用于心肌梗死(MI)40天以内的患者,因此在MI后过渡期管理期间可能不考虑予患者置入ICD治疗。美国学者近期在低射血分数(EF)老年MI患者中评估了ICD置入率和与其相关的死亡率,结果表明,在上述人群中,虽然ICD置入与2年时患者较低的校正死亡风险有关,但不到1/10的适宜患者在MI后1年内接受了ICD置入。相关论

置入心脏复律除颤器(ICD)不被推荐用于心肌梗死(MI)40天以内的患者,因此在MI后过渡期管理期间可能不考虑予患者置入ICD治疗。美国学者近期在低射血分数(EF)老年MI患者中评估了ICD置入率和与其相关的死亡率,结果表明,在上述人群中,虽然ICD置入与2年时患者较低的校正死亡风险有关,但不到1/10的适宜患者在MI后1年内接受了ICD置入。相关论文近日在线发表于《美国医学会杂志》(简称JAMA)。

该回顾观察性研究纳入了MI后EF≤35%的受试者10318例,排除了既往置入过ICD的患者。获取至2010年12月的患者随访数据。对MI后1年内置入ICD和未置入ICD的患者进行对比,以1年内接受ICD置入治疗相关的患者特征和2年死亡率作为主要评价指标。

结果显示,受试者累积1年ICD置入率为8.1% (95% CI, 7.6%-8.7%; n = 785)。与1年内未接受ICD置入患者相比,置入ICD的患者更可能是既往接受过冠状动脉旁路移植术(CABG)[31% vs 20%; 校正危险比(HR)1.49; 95% CI1.26-1.78],且其肌钙蛋白水平(中位数,正常值的85 vs 51倍;校正HR1.02/10倍增加;95% CI, 1.01-1.03)、院内心源性休克(13% vs 8%; 校正HR, 1.57; 95% CI, 1.25-1.97)和安装后2周内心脏病学随访率(30% vs 20%; 校正HR, 1.64; 95% CI, 1.37-1.95)均较高。ICD置入与2年死亡率较低有关[15.3事件/100患者-年(838例患者-年中有128例死亡)]vs[26.4事件/100患者-年(11 479例患者-年中有3033例死亡)];(校正HR 0.64; 95% CI, 0.53-0.78)。

原始出处:

Sean D. Pokorney, MD, MBA1,2; Amy L. Miller, MD, PhD3; Anita Y. Chen, MS2; Laine Thomas, PhD2; Gregg C. Fonarow, MD4; James A. de Lemos, MD5; Sana M. Al-Khatib, MD, MHS1,2; Eric D. Peterson, MD, MPH1,2; Tracy Y. Wang, MD, MHS, MSc1,2.Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction.JAMA.June 23/30, 2015.doi:10.1001/jama.2015.6409.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2053386, encodeId=5400205338632, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sun Dec 20 03:12:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860462, encodeId=c5db1860462d0, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sat Nov 14 07:12:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255521, encodeId=cc391255521b8, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jul 10 00:12:00 CST 2015, time=2015-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31767, encodeId=a4f131e67ac, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Jul 09 07:23:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31559, encodeId=aa7631559ec, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:09:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
    2015-12-20 lfyang
  2. [GetPortalCommentsPageByObjectIdResponse(id=2053386, encodeId=5400205338632, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sun Dec 20 03:12:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860462, encodeId=c5db1860462d0, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sat Nov 14 07:12:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255521, encodeId=cc391255521b8, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jul 10 00:12:00 CST 2015, time=2015-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31767, encodeId=a4f131e67ac, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Jul 09 07:23:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31559, encodeId=aa7631559ec, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:09:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
    2015-11-14 yilong5287542
  3. [GetPortalCommentsPageByObjectIdResponse(id=2053386, encodeId=5400205338632, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sun Dec 20 03:12:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860462, encodeId=c5db1860462d0, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sat Nov 14 07:12:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255521, encodeId=cc391255521b8, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jul 10 00:12:00 CST 2015, time=2015-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31767, encodeId=a4f131e67ac, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Jul 09 07:23:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31559, encodeId=aa7631559ec, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:09:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2053386, encodeId=5400205338632, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sun Dec 20 03:12:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860462, encodeId=c5db1860462d0, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sat Nov 14 07:12:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255521, encodeId=cc391255521b8, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jul 10 00:12:00 CST 2015, time=2015-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31767, encodeId=a4f131e67ac, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Jul 09 07:23:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31559, encodeId=aa7631559ec, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:09:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
    2015-07-09 owlhealth

    不错不错

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2053386, encodeId=5400205338632, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sun Dec 20 03:12:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860462, encodeId=c5db1860462d0, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sat Nov 14 07:12:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255521, encodeId=cc391255521b8, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jul 10 00:12:00 CST 2015, time=2015-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31767, encodeId=a4f131e67ac, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Jul 09 07:23:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31559, encodeId=aa7631559ec, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:09:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
    2015-07-08 huaxipanxing

    看看

    0

相关资讯

NEJM:长期应用替格瑞洛 显著降低既往心梗患者不良事件发生率

既往心梗患者长期使用替格瑞洛双抗血小板疗法,短期内的疗效已经被证实,但一年或者更长时间以后的效果仍未充分确立,大样本的数据研究更为缺乏。近日,一项发表于国际杂志New England Journal of Medicine上的研究论文借助大样本群体研究,证实了长期随访下替格瑞洛双抗的远期效果和安全性。替格瑞洛同氯吡格雷一样,属于P2Y12受体抑制剂,但是和前者稍有不同的是,替格瑞洛 属于可逆P2Y

NEJM:心梗患者长期使用替卡格雷效果好坏参半

    超过1年的心肌梗死后双重抗血小板治疗的潜在益处尚未建立。在这方面,我们研究替卡格雷的有效性和安全性,一种急性冠状动脉综合征之后既定功效的P2Y12受体拮抗剂。    我们随机分配,以双盲1:1:1的方式,21162例服用替卡格雷90毫克的剂量1至3年前每天两次有过心肌梗塞,替卡格雷为60毫克的剂量,每天两次,或安慰剂。所有患者均接受低剂量阿司匹林,并

7种方法降C反应蛋白 让心梗远离你

多年来医生都专注于用基本措施来评估患者的健康状况,如血压、体重、胆固醇水平等。但近年来更多的研究发现针对心脏健康出现了一种新的最有价值预测方法:C反应蛋白(CRP)。据menshealth.com网站报道,尽管早在1930年医生们就发现了这种由肝脏生成的血浆蛋白,但只是在前几年医学界才发现它很重要。现在医生已了解到体内的CRP水平能帮助评估慢性炎症及

NEJM:CTA检查不能改善冠脉疾病(CAD)治疗效果

背景:很多病人发生冠心病(CAD)之前会出现先兆症状,尽管通过随机试验得出诊断的数据很少,但大家普遍通过使用诊断性操作判断评估患者病情。方式:我们随机选取10003位出现冠心病先兆症状的患者接受冠状动脉CT血管造影(CTA)(我们称之为实验组)或功能性测试(使用运动心电图、核压力测试、负荷超声心动图)(我们称之为对照组)进行试验。我们关注的主要指标是患者死亡率、心肌梗塞和因不稳定性心绞痛住院、出现

Circulation:急性心梗后阿司匹林剂量对治疗效果的影响

    背景  阿司匹林是广泛使用于心肌梗死(MI)抗血小板的药物,但其经皮冠状动脉介入治疗(PCI)术最佳的维持剂量仍存在不确定性。    方法和结果  研究人员比较了在2010-2012年间在TRANSLATE-ACS研究中228家美国医院的10213名经历了PCI的心梗患者,并在出院后进行双重抗血小板治疗的结果。主要不良心血管事件(

Circulation:冠脉搭桥手术后的病人长期服用β受体阻滞剂有无必要?

对于正在行冠状动脉旁路移植术(冠脉搭桥,CABG)的患者,术后长期应用β受体阻滞剂的必要性和有效性一直争议不断。最近的一些观察性研究也显示出了相矛盾的结果。出院后病人要不要长期服药,这让心外的医师在写出院医嘱时困惑不已。到底CABG病人出院后需不需要长期服用β受体阻滞剂?来自于中国北京协和医院和阜外心血管病医院的研究者们最近在Circulation杂志发表了一篇文章,针对这个问题给出了证据充足的回

Baidu
map
Baidu
map
Baidu
map